GreenLight Biosciences expands RTP footprint for next generation agricultural products


BOSTON, January 7, 2022 /PRNewswire/ — GreenLight Biosciences, a biotechnology company specializing in the research, design and manufacturing of RNA for human, animal and plant health, today announced the expansion of its research and development activities in Research Triangle Park (RTP), North Carolina.

GreenLight Biosciences expands RTP footprint for next generation agricultural products

The new greenhouse, lab and offices will add over 60,000 square feet of space and enable the continued growth of GreenLight’s plant health pipeline, creating more jobs.

“This additional capacity is a critical step in helping us capitalize on our agriculture solutions to realize a food secure future,” says Marc Singleton, Head of Plant Health at RTP. “The investment will help us stay at the forefront of innovation and pursue unprecedented advancements as we are currently seeing in our fungal program.”

“We expect to have 60 staff on site by the end of 2022, with our new spaces housing various entomology, fungi and herbicide projects and the functions that support them.”

“GreenLight epitomizes the type of business we envision for our center in Alexandria® for the AgTech campus, a fully integrated, facility-rich R&D and greenhouse campus,” said Blake StevensVice President of Science and Technology, Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments.

“With the transformative potential of GreenLight’s RNA platform, we have both invested in and provided the company with mission-critical real estate, and we are excited to support their rapid growth and efforts to improve significantly human health and nutrition in the second phase of our first-of-its-kind agtech campus.”

Occupancy of the new greenhouse, where GreenLight will plant a variety of crops, will begin in the first quarter and will increase the capacity for growth tenfold. The operations will support research and product development as the company strives to bring innovative new tools to farmers to control pests and diseases, including botrytis and powdery mildew.

In 2022, GreenLight awaits regulatory approval of its RNA-based product to control the Colorado Colorado potato beetle and submit its bee health solution to the Environmental Protection Agency.

The company has seven agricultural products in development with an addressable market of $6 billion which it plans to launch by 2026. In October, GreenLight announced that effective control of fungal pathogens using double-stranded RNA had been achieved for the first time.

About GreenLight
Founded in 2008, GreenLight aims to solve some of the world’s biggest problems by harnessing the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutics. In agriculture, this includes RNA to protect bees and a range of crops. The company’s revolutionary cell-free RNA manufacturing platform, which is protected by numerous patents, enables cost-effective production of RNA. GreenLight’s human health product candidates are in the preclinical stage, and its agricultural market product candidates are in the early stages of development or regulatory review. For more information visit

In August 2021GreenLight Biosciences announced plans to go public through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, with respect to the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquiring (“ENVI”). These forward-looking statements are generally identified by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity “, “plan,” “may,” “should,” “will,” “would,” “will,” “continue,” “probably result,” and similar expressions. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this press release, including, but not limited to, the risk that the transaction may not be completed in a timely manner or at all, which could adversely affect the price of ENVI’s securities and the effect of the announcement or expectation of the transaction on GreenLight’s business relationships, results of operations and business generally. Forward-looking statements speak only as of the date to which they are made. Readers are cautioned not to rely unduly to forward-looking statements, and ENVI and GreenLight undertake no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.



View original content to download multimedia:

SOURCEGreenLight Biosciences, Inc.

Source link


Comments are closed.